Volanesorsen for treating familial chylomicronaemia syndrome (HST13)
Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults
Search results
1538 results
-
-
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655)
Evidence-based recommendations on nivolumab (Opdivo) for advanced squamous non-small-cell lung cancer in adults after chemotherapy
-
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (TA653)
Evidence-based recommendations on osimertinib (Tagrisso) for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or
-
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654)
Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive
-
Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal) (TA652)
NICE is unable to make a recommendation on alpelisib (Piqray) with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced
-
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)
Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults
-
Naldemedine for treating opioid-induced constipation (TA651)
Evidence-based recommendations on naldemedine (Rizmoic) for treating opioid-induced constipation in adults who have had laxative treatment
-
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (TA649)
Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
-
Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA648)
NICE is unable to make a recommendation on dupilumab (Dupixent) for treating chronic rhinosinusitis with nasal polyps because Sanofi did not provide an evidence
-
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)
Evidence-based recommendations on avelumab (Bavencio) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults
-
Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) (TA646)
NICE is unable to make a recommendation on glasdegib with chemotherapy for untreated acute myeloid leukaemia because Pfizer did not provide an evidence
-
Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal) (TA647)
NICE is unable to make a recommendation about the use in the NHS of eculizumab (Soliris) for treating relapsing neuromyelitis optica because Alexion Pharma UK
-
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)
Evidence-based recommendations on brentuximab vedotin (Adcetris) with cyclophosphamide, doxorubicin and prednisone for untreated systemic anaplastic large cell
-
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)
Evidence-based recommendations on gilteritinib (Xospata) for relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults
-
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)
Evidence-based recommendations on entrectinib (Rozlytrek) for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1
-
Entrectinib for treating NTRK fusion-positive solid tumours (TA644)
Evidence-based recommendations on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and
-
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)
Evidence-based recommendations on treosulfan (Trecondi) with fludarabine for conditioning treatment before allogeneic haematopoietic stem cell transplant for
-
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638)
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults
-
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639)
Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic
-
Eculizumab for treating refractory myasthenia gravis (terminated appraisal) (TA636)
NICE is unable to make a recommendation on eculizumab (Soliris) for treating refractory myasthenia gravis because Alexion Pharma UK did not provide an evidence
-
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal) (TA634)
NICE is unable to make a recommendation on daratumumab (Darzalex) with lenalidomide and dexamethasone for untreated multiple myeloma, because Janssen did not
-
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) (TA635)
NICE is unable to make a recommendation on ramucirumab (Cyramza) with erlotinib for untreated epidermal growth factor receptor (EGFR)-positive metastatic non
-
Ranibizumab for treating diabetic retinopathy (terminated appraisal) (TA637)
NICE is unable to make a recommendation about the use in the NHS of ranibizumab (Lucentis) for treating diabetic retinopathy because Novartis did not provide an
-
Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)
Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive
-
Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)
Evidence-based recommendations on ustekinumab (Stelara) for treating moderately to severely active ulcerative colitis in adults
-
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in adults who
-
Fremanezumab for preventing migraine (TA631)
This guidance has been updated and replaced by NICE technology appraisal guidance 764.
-
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)
Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and
-
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)
Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults
-
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months
-
Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)
Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults
-
Alemtuzumab for treating highly active relapsing remitting multiple sclerosis (TA312)
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.
-
Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal) (TA625)
NICE is unable to make a recommendation on recombinant human parathyroid hormone for treating hypoparathyroidism because Shire Pharmaceuticals
-
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)
Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults
-
Patiromer for treating hyperkalaemia (TA623)
Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults
-
Sotagliflozin with insulin for treating type 1 diabetes (TA622)
Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2
-
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621)
This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 654
-
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)
Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
-
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) (TA618)
NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) with carboplatin and nab-paclitaxel for untreated advanced NSCLC
-
Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA620)
Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal
-
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)
Evidence-based recommendations on lusutrombopag (Mulpleo) for severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure
-
Cladribine for treating relapsing–remitting multiple sclerosis (TA616)
Evidence-based recommendations on cladribine (Mavenclad) for relapsing–remitting multiple sclerosis (RRMS) in adults
-
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older
-
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome (DS) in people aged 2 years and older
-
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children
-
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (TA613)
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema that has inadequately responded to
-
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (TA612)
Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2
-
Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)
Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults
-
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)
Evidence-based recommendations on rucaparib (Rubraca) for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer that has
-
Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) (TA608)
NICE is unable to make a recommendation about the use in the NHS of ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults